Open Access

Targeting the Hippo pathway to prevent radioresistance brain metastases from the lung (Review)

  • Authors:
    • Jasmine Taylor
    • Fatéméh Dubois
    • Emmanuel Bergot
    • Guénaëlle Levallet
  • View Affiliations

  • Published online on: May 17, 2024     https://doi.org/10.3892/ijo.2024.5656
  • Article Number: 68
  • Copyright: © Taylor et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The prognosis for patients with non‑small cell lung cancer (NSCLC), a cancer type which represents 85% of all lung cancers, is poor with a 5‑year survival rate of 19%, mainly because NSCLC is diagnosed at an advanced and metastatic stage. Despite recent therapeutic advancements, ~50% of patients with NSCLC will develop brain metastases (BMs). Either surgical BM treatment alone for symptomatic patients and patients with single cerebral metastases, or in combination with stereotactic radiotherapy (RT) for patients who are not suitable for surgery or presenting with fewer than four cerebral lesions with a diameter range of 5‑30 mm, or whole‑brain RT for numerous or large BMs can be administered. However, radioresistance (RR) invariably prevents the action of RT. Several mechanisms of RR have been described including hypoxia, cellular stress, presence of cancer stem cells, dysregulation of apoptosis and/or autophagy, dysregulation of the cell cycle, changes in cellular metabolism, epithelial‑to‑mesenchymal transition, overexpression of programmed cell death‑ligand 1 and activation several signaling pathways; however, the role of the Hippo signaling pathway in RR is unclear. Dysregulation of the Hippo pathway in NSCLC confers metastatic properties, and inhibitors targeting this pathway are currently in development. It is therefore essential to evaluate the effect of inhibiting the Hippo pathway, particularly the effector yes‑associated protein‑1, on cerebral metastases originating from lung cancer.
View Figures
View References

Related Articles

Journal Cover

July-2024
Volume 65 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Taylor J, Dubois F, Bergot E and Levallet G: Targeting the Hippo pathway to prevent radioresistance brain metastases from the lung (Review). Int J Oncol 65: 68, 2024.
APA
Taylor, J., Dubois, F., Bergot, E., & Levallet, G. (2024). Targeting the Hippo pathway to prevent radioresistance brain metastases from the lung (Review). International Journal of Oncology, 65, 68. https://doi.org/10.3892/ijo.2024.5656
MLA
Taylor, J., Dubois, F., Bergot, E., Levallet, G."Targeting the Hippo pathway to prevent radioresistance brain metastases from the lung (Review)". International Journal of Oncology 65.1 (2024): 68.
Chicago
Taylor, J., Dubois, F., Bergot, E., Levallet, G."Targeting the Hippo pathway to prevent radioresistance brain metastases from the lung (Review)". International Journal of Oncology 65, no. 1 (2024): 68. https://doi.org/10.3892/ijo.2024.5656